Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on ALNY stock, giving a Buy rating today.

Jessica Fye’s rating is based on the promising outlook for Alnylam Pharma’s Amvuttra, particularly in the ATTR-CM market. The increasing diagnosis rates and the expected rise in the use of branded agents suggest a growing market opportunity. Dr. Carlos Santos-Gallego’s insights highlight a strong preference for Amvuttra among newly diagnosed patients and those progressing on tafamidis, indicating a potential boost in its adoption.
Furthermore, the forecasted sales for the silencer class in ATTR-CM and ATTR-PN markets underscore the significant revenue potential for Alnylam. The expected growth in the diagnosis of ATTR-CM, coupled with the economic advantages of prescribing Amvuttra, supports a favorable market environment. Overall, the combination of a robust product pipeline and a proven platform contributes to the Buy rating for Alnylam Pharma.

In another report released today, Barclays also maintained a Buy rating on the stock with a $329.00 price target.

Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.